Abstract
Latent toxoplasmosis always has the risk of reactivation leading to significant sequelae. The available medications, for chronic toxoplasmosis, are awfully limited by resistance of Toxoplasma cysts. Therefore, there is a growing necessity for novel therapeutic approaches. Agents increasing cAMP levels and downregulating proinflammatory cytokine could inhibit Toxoplasma conversion to the bradyzoite stage. This study explores a potential immunomodulatory effect of rolipram, a PDE4 inhibitor, on the course of experimental toxoplasmosis and links this role to deterrence of the resistant chronic phase of the disease. Mice infected with low pathogenic strain of Toxoplasma gondii were treated with rolipram for three weeks. The effect of rolipram was evaluated through tissue injury scoring, brain cyst count, specific IgG titers as well as TNF-α, IFN-γ and IL-12 assays. Rolipram was partially able to prevent the progression to chronic toxoplasmosis. Toxoplasma brain cyst burden showed a 74% reduction while Toxoplasma-induced inflammatory foci per liver area and nucleated cells per inflammatory focus were significantly reduced: 57.14% and 61.3% respectively. Significant reduction of TNF-α (84.6%), IFN-γ (76.7%) and IL-12 (71%) levels was...Continue Reading
References
Jan 1, 1980·Antonie van Leeuwenhoek·F van Knapen, S O Panggabean
Nov 26, 1997·Journal of Virology·J S OrangeC A Biron
Aug 6, 2000·Japanese Journal of Pharmacology·T MoriT Suzuki
Sep 29, 2000·Progress in Nucleic Acid Research and Molecular Biology·S H FrancisJ D Corbin
Dec 19, 2000·Infection and Immunity·L A KirkmanK Kim
Feb 13, 2001·Clinical Immunology : the Official Journal of the Clinical Immunology Society·E BeshayG J Prud'homme
Feb 17, 2001·Infection and Immunity·M I AraujoE J Pearce
Mar 23, 2002·Microbes and Infection·Neide M SilvaRicardo T Gazzinelli
May 23, 2002·The Journal of Infectious Diseases·Tanya V AspinallPaul F G Sims
May 29, 2002·Proceedings of the National Academy of Sciences of the United States of America·S-L Catherine Jin, Marco Conti
Mar 17, 2004·Trends in Pharmacological Sciences·James M O'Donnell, Han-Ting Zhang
Aug 13, 2005·Veterinary Parasitology·Milton M McAllister
Jun 13, 2006·Ocular Immunology and Inflammation·Holger BaatzLars-Olof Hattenbach
Feb 27, 2007·Schizophrenia Bulletin·Vern B Carruthers, Yasuhiro Suzuki
Sep 8, 2009·TheScientificWorldJournal·Tariq F Al-Shaiji, Gerald B Brock
Feb 13, 2010·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Mahesh ShivannaSangly P Srinivas
Jul 30, 2011·PloS One·Hitomi KurokawaHiroomi Akashi
Nov 19, 2011·FEMS Microbiology Reviews·William J Sullivan, Victoria Jeffers
May 15, 2012·Pharmacological Reports : PR·Marianna SzczypkaBożena Obmińska-Mrukowicz
Apr 6, 2013·BMC Medicine·Neal KumarAlice B Gottlieb
Mar 26, 2014·PloS One·Jaroslav FlegrZafar H Israili
Citations
Feb 7, 2017·Frontiers in Microbiology·Mahbobeh MontazeriAhmad Daryani
Feb 26, 2020·Food and Waterborne Parasitology·Neda KonstantinovicFlorence Robert-Gangneux
Jun 11, 2021·Frontiers in Microbiology·Edwin LasonderChetan E Chitnis